Bio­Mar­in's Roc­ta­vian, once fore­cast to sell $50M to $150M last year, on­ly pulls in a frac­tion of that

In April, Bio­Marin fore­cast that its new gene ther­a­py Roc­ta­vian would bring in $50 mil­lion to $100 mil­lion in sales by the end of 2023 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.